Navigation Links
Codexis Expands Pharmaceutical Manufacturing Partnerships

REDWOOD CITY, Calif., Feb. 17 /PRNewswire/ -- Codexis, Inc. today announced two separate collaborations in pharmaceutical manufacturing with Dishman Pharmaceuticals and Chemicals and AMPAC Fine Chemicals LLC (AFC), a subsidiary of American Pacific Corporation. These agreements expand the application of Codexis technology to a broadened pipeline of branded innovator pharmaceutical products.

Under the new agreements, Codexis will apply its proprietary biocatalyst technology to selected therapeutic products in the collaborators' portfolios to reduce cost, increase manufacturing efficiency and lessen environmental impact.  Codexis technology is used at innovator pharmaceutical companies to enable cost-effective manufacturing processes at commercial scale.

Dishman, headquartered in Ahmedabad, India, is a global outsourcing partner manufacturing active pharmaceutical ingredients (APIs) and intermediates for the pharmaceutical industry.  Dishman operates 12 API and intermediate production facilities in India, China, Switzerland and the UK manufacturing products for leading global innovator drug companies worldwide.  Under the terms of the agreement, Codexis and Dishman will work exclusively to supply intermediates and active ingredients manufactured using Codexis technology to a select group of innovators; Dishman will be Codexis' preferred CMO partner for new opportunities at other innovators.  

AFC, headquartered in Rancho Cordova, CA, is a custom manufacturer of pharmaceutical fine chemicals.  The company specializes in technology using high energetic chemistry and other specific technologies which are advantageous for certain classes of products.  

"These new partnerships bring Codexis technology to an expanded portfolio of innovator pharmaceutical products.  They will be important as we continue to serve our pharmaceutical customers worldwide," said Alan Shaw, Ph.D., President and Chief Executive Officer.

Codexis, Inc. is a leading provider of optimized biocatalysts that make existing industrial processes faster, cleaner and more efficient than current methods and have the potential to make new industrial processes possible at commercial scale.  Codexis has commercialized its biocatalysts in the pharmaceutical industry and is developing biocatalysts for use in producing advanced biofuels under a multi-year research and development collaboration. The company is also using its technology platform to pursue biocatalyst-enabled solutions in other bioindustrial markets, including carbon management, water treatment and chemicals. 

Contact: Lyn Christenson,, 650-421-8144 or Saskia Sidenfaden,, 212-827-3771.

SOURCE Codexis, Inc.



SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Codexis Names Fernando Valle Research Fellow
2. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
3. Codexis Expands Collaboration with Teva
4. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
5. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
6. Cellectar Expands Clinical Management Team
7. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
8. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
9. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
10. PAREXEL Expands Global Clinical Pharmacology Capabilities
11. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
Post Your Comments:
(Date:11/24/2015)... iRhythm Technologies, Inc. , a leading digital health care solutions ... participate in the 27th Annual Piper Jaffray Healthcare Conference at The ... . Kevin King , Chief Executive Officer of iRhythm, ... ET. --> --> About ... . --> iRhythm is a privately held digital ...
(Date:11/24/2015)... , Nov. 24, 2015 Teledyne DALSA ... X-Ray image sensing technology, will introduce its CMOS X-Ray ... Exhibition , November 29 to December 3, at McCormick Place ... dynamic detectors for diagnostic and interventional imaging will be on ... Xineos family of advanced CMOS X-Ray detectors is the ...
(Date:11/24/2015)... The uptake of recently approved and pipeline premium products for Type 1 ... 2021, says GBI Research . --> ... Diabetes Mellitus (T1DM), will be a key driver of market growth to ... The uptake of recently approved and pipeline premium products for Type ... to 2021, says GBI Research . ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... It takes only three to five ... is critical that the first impression be positive and reflects business values. If a ... buy anything or want to return. They will also share their thoughts about a ...
(Date:11/24/2015)... PLAINSBORO, N.J. (PRWEB) , ... November 24, 2015 ... ... experts will gather to share their knowledge and experiences at a live taping ... during the Ruesch Center for the Cure of Gastrointestinal Cancers 2015 Symposium at ...
(Date:11/24/2015)... ... 24, 2015 , ... Aided by seed funding from the Ron Foley Foundation, ... yield insights into how to detect and treat pancreatic cancer (PC). , WCHN ... non-coding RNA molecules (ncRNA), genetic material that is present in the blood of patients ...
(Date:11/24/2015)... ... November 24, 2015 , ... Sir Grout of Baltimore ... TrustDale certification. The award recognizes good companies for excellence in service and a ... grout, and hard surface restoration company earned this recognition after a thorough review ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... of patented products, announces Innovative Blending, a household invention that revolutionizes the vending ... Juice & Smoothie Bars market is worth $2 billion," says Scott Cooper, CEO ...
Breaking Medicine News(10 mins):